Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New applications of disease genetics and pharmacogenetics to drug development.

Current opinion in pharmacology - 1 Feb 2014

Roses Allen D, Saunders Ann M, Lutz Michael W, Zhang Nanyin, Hariri Ahmad R, Asin Karen E, Crenshaw Donna G, Budur Kumar, Burns Daniel K, Brannan Stephen K

Abstract excerpt

TOMMORROW is a Phase III delay of onset clinical trial to determine whether low doses of pioglitazone, a molecule that induces mitochondrial doubling, delays the onset of MCI-AD in normal subjects treated with low dose compared to placebo. BOLD imaging studies in rodents and man were used to find...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Alzheimer Disease
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cognitive Dysfunction

Share to Drug Design

Share to Pharmacogenetics

Share to Pioglitazone

Share to Thiazolidinediones

Source

Identifiers

PMID: 24565016
DOI: 10.1016/j.coph.2013.12.002

Genes

APOE
TOMM40

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24565016-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

New applications of disease genetics and pharmacogenetics to drug development.PMID 24565016Read ↗

Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).Semantic proximity Read ↗

Opportunities in pharmacogenomics for the treatment of Alzheimer’s diseaseSemantic proximity Read ↗

Pharmacogenetic Basis for Therapeutic Optimization in Alzheimer’s DiseaseSemantic proximity Read ↗

Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomization studySemantic proximity Read ↗

Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation studySemantic proximity Read ↗

Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome.Semantic proximity Read ↗

Pharmacogenomics and therapeutic strategies for dementiaSemantic proximity Read ↗

Risk of Alzheimer's disease and genetically predicted levels of 1400 plasma metabolites: a Mendelian randomization study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.